Journal of Clinical Medicine (Jul 2021)

Review and Updates on the Treatment of Refractory and Super Refractory Status Epilepticus

  • Yazeed S. Alolayan,
  • Kelly McKinley,
  • Ritwik Bhatia,
  • Ayham Alkhachroum

DOI
https://doi.org/10.3390/jcm10143028
Journal volume & issue
Vol. 10, no. 14
p. 3028

Abstract

Read online

Refractory and super-refractory status epilepticus (RSE and SRSE) are life-threatening conditions requiring prompt initiation of appropriate treatment to avoid permanent neurological damage and reduce morbidity and mortality. RSE is defined as status epilepticus that persists despite administering at least two appropriately dosed parenteral medications, including a benzodiazepine. SRSE is status epilepticus that persists at least 24 h after adding at least one appropriately dosed continuous anesthetic (i.e., midazolam, propofol, pentobarbital, and ketamine). Other therapeutic interventions include immunotherapy, neuromodulation, ketogenic diet, or even surgical intervention in certain cases. Continuous electroencephalogram is an essential monitoring tool for diagnosis and treatment. In this review, we focus on the diagnosis and treatment of RSE and SRSE.

Keywords